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Background: Atopaxar (E5555) is a reversible protease activated receptor (PAR)-1 thrombin receptor antagonist that interferes with platelet 
signaling. The effects of atopaxar on biomarkers of inflammation and platelet activation remain unknown.
Methods: The LANCELOT-CAD trial randomized 720 subjects and the J-LANCELOT (CAD) trial randomized 263 subjects with CAD to atopaxar (50mg, 
100mg, or 200mg daily) or placebo for 24 weeks. Biomarkers were assessed at serial timepoints. Treatment differences between active treatment 
and placebo were based on least square means from ANCOVA models.
Results: The soluble CD40 ligand (sCD40L, a marker of platelet activation) concentration decreased by 10.5% in the atopaxar group at 4 weeks, 
versus a 1.6% rise for placebo (P=0.028) in LANCELOT-CAD (Figure); however, these findings were not seen in J-LANCELOT. In contrast, Lp-PLA2 mass 
rose by week 2 by 2.7% in the atopaxar group versus a 1.2% decrease in the placebo arm (P=0.03). Similarly, the concentration of IL-18 rose by 
4.0% in the atopaxar group versus a 1.8% fall in the placebo group by week 4 (P=0.016). The effects of atopaxar on Lp-PLA2 and IL-18 were dose-
dependent and were confirmed in J-LANCELOT. Atopaxar did not have a significant effect on other markers.
Conclusion: Atopaxar decreased sCD40L, but did not demonstrate a clear anti-inflammatory effect on other established biomarkers. Although 
atopaxar increased the concentration of Lp-PLA2 and IL-18, the clinical relevance of these findings remains unknown.
 
